1. Home
  2. VWAV vs KPTI Comparison

VWAV vs KPTI Comparison

Compare VWAV & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VWAV

VisionWave Holdings Inc.

N/A

Current Price

$10.28

Market Cap

152.5M

Sector

Technology

ML Signal

N/A

Logo Karyopharm Therapeutics Inc.

KPTI

Karyopharm Therapeutics Inc.

HOLD

Current Price

$6.59

Market Cap

148.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VWAV
KPTI
Founded
2024
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
152.5M
148.0M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
VWAV
KPTI
Price
$10.28
$6.59
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$22.17
AVG Volume (30 Days)
470.9K
420.4K
Earning Date
02-26-2026
02-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$142,530,000.00
Revenue This Year
N/A
$3.82
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.06
$3.51
52 Week High
$18.41
$10.75

Technical Indicators

Market Signals
Indicator
VWAV
KPTI
Relative Strength Index (RSI) N/A 45.78
Support Level N/A $5.88
Resistance Level N/A $8.95
Average True Range (ATR) 0.00 0.68
MACD 0.00 -0.19
Stochastic Oscillator 0.00 23.58

Price Performance

Historical Comparison
VWAV
KPTI

About VWAV VisionWave Holdings Inc.

VisionWave Holdings Inc is engaged in revolutionizing defense capabilities by integrating artificial intelligence (AI) and autonomous solutions across air, ground, and sea domains. Its innovations range from high-resolution radars and vision systems to radio frequency (RF) sensing technologies are seeking to redefine operational efficiency and precision for military and homeland security applications globally.

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Share on Social Networks: